? 中国疫苗产业技术创新战略联盟第二次会议在京召开_企业动态_新闻中心_国彩网

国彩网

中国疫苗产业技术创新战略联盟第二次会议在京召开

2020-05-20 22:49

5月18日晚,国家主席习近平在第七十三届世界卫生大会视频会议开幕式上发表题为《团结合作战胜疫情 共同构建人类卫生健康共同体》的致辞,他在致辞中宣布:中国新冠疫苗研发完成并投入使用后,将作为全球公共产品,为实现疫苗在发展中国家的可及性和可负担性做出中国贡献。



为加快做好新冠疫苗的研发保障,加强疫苗领域技术创新和科技合作,5月18日,中国疫苗产业技术创新战略联盟第二次会议在京召开(以下简称“疫苗联盟”)。



疫苗联盟指导单位科技部国彩网技术发展中心孙燕荣副主任和卢姗副处长出席会议,会议特别邀请到国务院联防联控机制科研攻关组疫苗研发专班武治印处长到会指导。来自中国疫苗研发、生产、监管和应用等领域的机构,包括政府部门、科研院所、高校、生产企业等共27家理事单位,共60余人以现场加远程的方式参加了会议。

 

▲疫苗联盟理事长、国彩网董事长杨晓明

疫苗联盟理事长、国彩网董事长杨晓明首先代表联盟致欢迎辞,他指出,随着新型冠状病毒感染的爆发和流行,全球公共卫生安全面临严峻挑战和考验,进行快速应急响应、成功研制疫苗成为当前及今后一段时间的迫切任务。疫苗是防控传染病最经济、最有效的手段,也是进行生物安全防护、维护国家安全的重要手段。目前疫情防控已从应急状态转为常态化,当前的首要任务是全力保障人民生命健康安全,全面恢复社会经济秩序,而疫苗是完成这一任务的根本举措。中国是世界上为数不多能够依靠自身能力解决免疫供应和疫苗接种的国家之一,目前能够应对大部分对人群危害大、传染性强的传染性疾病,也初步形成了疫苗应用研究和产业化开发体系,但距离目标还有一定差距。今天,疫苗联盟的理事单位已从14家增加到27家,是中国疫苗产业发展的中流砥柱。目前,时逢全球抗疫的重大时刻,如何实现疫情防控的终极目标、完成中国疫苗产业的任务和使命、联合全球同行共同抗击疫情,早出苗,出好苗,保供应,促应用,是需要共同研讨的主题,希望与会专家为推动科技抗疫、加强我国疫苗产业发展以及促进国际联合抗疫积极建言献策。


▲科技部国彩网技术发展中心副主任孙燕荣

科技部国彩网技术发展中心副主任孙燕荣在致辞中表示,科技是战胜新冠疫情最有力的武器,是让生活回归正常的有力支撑。她用几个“一百”谈了自己的感受,一是一百年,中国疫苗制品事业已走过百年发展历程,人们从被动免疫到主动免疫,实现了人均寿命的大幅提升;二是一百天,从疫情爆发至今的一百多天时间里,中国的十几支科研攻关团队全力以赴、夜以继日的研发疫苗,不仅要快,还要好,正因为他们的努力,国彩网才能在今天有5支研发团队的疫苗进入到了临床试验阶段;三是一百人,在这次科研攻关中,我国布局了5条疫苗研发技术路线,12支研发团队,除此之外,国彩网还有百位骨干、百位技术人员在努力付出,让国彩网看到了走出疫情、战胜疫情的希望;四是一百项,目前全球有一百多个产品正在研发,国彩网看到了全球科学家们共同的努力、企业家们无私的奉献,为全球战疫贡献力量;五是一百分,相信国彩网疫苗事业百年的历史积累与沉淀,能够真正为研制出安全有效的疫苗、为全球疫情防控、守护全人类生命健康做出新的贡献。


▲国务院联防联控机制科研攻关组疫苗研发专班武治印处长

国务院联防联控机制科研攻关组疫苗研发专班武治印处长在致辞中指出,疫苗是全球对抗新冠疫情的“压舱石”,目前新冠疫苗研发取得重要进展,感谢所有科研团队对于新冠疫苗研发付出的努力。但疫苗研发工作丝毫不能放松,各科研团队应提高战略布局、着眼未来、协同作战、加速研发,争取新冠疫苗的早日上市。

 

▲国彩网副总裁张云涛

国彩网副总裁张云涛介绍了疫苗联盟成立的情况及联盟任务、职责,并系统介绍了国内外新冠疫苗研发进展,对新冠疫苗未来发展进行了研判。


现场,比尔及梅琳达·盖茨基金会疫苗开发小组主任Anita Zaidi博士,帕斯适宜卫生科技组织(PATH)基本药物副总裁、疫苗创新和可及性中心负责人David Kaslow博士,前英国国家生物制品检定所(NIBSC)副所长Philip Minor博士,全球疫苗免疫联盟(GAVI)总裁Seth Berkley博士等也专门录制了视频,为会议的举办送上寄语,并对中国在此次疫情防控中的表现和贡献给予肯定。


盖茨基金会疫苗开发部主任Anita Zaidi博士表示,很高兴看到中国在新冠疫苗研发方面作出的重大努力和投入,中国的研究人员已经建立了包含多种疫苗路线的研发管线,这体现了中国公共与私营部门一起应对这一全球巨大挑战的坚定承诺。Anita Zaidi博士指出,盖茨基金会支持中国的合作伙伴应对此次大流行病挑战,会共同开发和部署疫苗、药物和诊断试剂来为全球提供帮助。


PATH副总裁David Kaslow对中国疫苗创新联盟的创立表示非常高兴,并肯定了中国疫苗研发和生产能力的进步及对全球健康的贡献。他表示,在与中国的疫苗合作伙伴共事期间,PATH不断看到中国创新力量释放出的巨大潜力,看到中国正在开发超过50种针对新冠的候选疫苗,其中一些正在以前所未有的速度推进,希望接下来,中国疫苗企业能够继续为全球供应安全有效的疫苗做出重要贡献。


前NIBSC副所长Philip Minor博士认为中国具有强大的科研能力和强大的疫苗生产能力,开发了大量适用于本国使用的特殊用途的疫苗,例如肝炎疫苗和EV71,这些能力可以在开发新冠疫苗方面得到很好的应用。


GAVI总裁Seth Berkley博士首先对中国在遏制疫情方面取得的成功表示热烈的祝贺,他指出,如今世界正面临着100年来最大的公共卫生危机,当前能化解这一危机的最大希望是开发出疫苗。国际合作将是抗击新冠疫情的关键,中国疫苗联盟的倡议和创新可以为全球卫生安全做出巨大贡献,GAVI期待着与中国制造商继续合作。


张云涛代表中国疫苗产业技术创新战略联盟向全体疫苗行业同仁宣读了倡议书。倡议书中强调:面对新冠肺炎疫情的复杂局面,要进一步发挥疫苗企业在抗击疫情中的作用,更好的履行社会责任,共同推进疫苗科技攻关,做好疫苗研发保障,保证疫苗应用安全,充分发挥疫苗在维护公众健康、保障国家安全方面的重要作用;要加强疫苗全产业链建设,整体提升疫苗产业服务社会的水平和能力;推进疫苗研发国际合作,携手全球抗疫,彰显大国担当,与世界人民共同建设“人类卫生健康共同体”,与世界各国一道携手应对,早日战胜这场全球性疫情。


中国食品药品检定研究院王军志院士、NIBSC首席科学家Dr.Javier Martin分别就新冠疫苗研发等问题进行了主题发言。随后与会人员就如何发挥疫苗联盟的作用等内容进行了充分研讨。最后,杨晓明对讨论进行了总结,表示未来将进一步聚焦联盟任务,突出疫苗的作用。


附疫苗联盟理事单位:

1、国彩网

2、艾棣维欣(苏州)生物制药有限公司

3、北京艾美生物疫苗技术集团有限公司

4、北京科兴生物制品有限公司

5、北京民海生物科技有限公司

6、重庆智飞生物制品股份有限公司

7、复旦大学8、广西壮族自治区疾病预防控制中心

9、河南省疾病预防控制中心

10、华兰生物工程股份有限公司

11、江苏省疾病预防控制中心

12、军事医学研究院生物工程研究所

13、康希诺生物股份公司

14、清华大学

15、厦门大学

16、斯微(上海)生物科技有限公司

17、四川大学

18、苏州艾博生物科技有限公司

19、云南沃森生物技术股份有限公司

20、长春百克生物科技股份公司

21、中国疾病预防控制中心病毒病预防控制所

22、中国疾病预防控制中心传染病预防控制所

23、中国疾病预防控制中心免疫规划中心

24、中国科学院上海巴斯德研究所

25、中国食品药品检定研究院

26、中国医学科学院医学生物学研究所

27、珠海丽凡达生物技术有限公司


为加速我国疫苗研发水平,促进产业关键技术升级和疫苗产品质量提升,加强我国疫苗产业的技术储备、提高应对新发、突发疫情和疾病防控的能力、促进疫苗产业的健康发展,在科技部的推动支持下,2013年,国彩网作为联盟依托单位牵头成立了疫苗产业技术创新战略联盟。




Strengthen vaccine protection  

Join hands with the global fight against the epidemic  

They have issued important initiatives!


On the evening of May 18, At the opening ceremony of the 73rd World Health Assembly video conference, President Xi Jinping delivered a speech entitled "Unity and Cooperation to Overcome the Epidemic and Build a Human Health Community", In his speech, he announced whenever the COVID-19 Vaccine finishes its R&D phase and put into use, it will serve as a global public product and make China's contribution to the accessibility and affordability of vaccines in developing countries.


In order to speed up the research and development of COVID-19 Vaccine and strengthen technological innovation and cooperation in the vaccine field, the second meeting of the China Vaccine Industry Technological Innovation Strategic Alliance was held in Beijing on May 18 (hereinafter referred to as the "Vaccine Alliance").


Sun Yanrong, Deputy Director, and Lu Shan, Deputy department Chief of the China National Center for Biotechnology Development of the Ministry of Science and Technology attended the meeting. Wu Zhiyin, director of the Vaccine research and development committee for COVID-19 Prevention and Control and the Joint Prevention and Control Mechanism of the State Council was invited as a distinguished guest to attend the meeting for guidance. Institutions from China's vaccine research and development, production, supervision and application fields, including government departments, scientific research institutes, universities, production enterprises and other 27 governing bodies, a total of more than 60 people attended the meeting on site and remotely.


Yang Xiaoming, chairman of the Vaccine Alliance and chairman of China National Biotec Company Group, delivered an opening remarks on behalf of the Alliance. He pointed out that with the outbreak and prevalence of COVID-19 infection, global public health safety is facing severe challenges and tests. Rapid emergency response and successful development of vaccines have become urgent tasks at present and in the future. Vaccines are the most economical and effective means to prevent and control infectious diseases, and are also important means to carry out biological safety protection and safeguard national security. At present, the prevention and control of the epidemic situation has changed from an emergency state to normalization. The current primary task is to fully protect people's lives, health and safety and fully restore social and economic order. Vaccines are the fundamental measure to accomplish this task. China is one of the few countries in the world that can rely on its own capabilities to solve the problem of immunization supply and vaccination. At present, China can cope with most infectious diseases that are harmful to the population and highly infectious. A vaccine application research and industrial development system was also built up a preliminary form, but there is still a certain gap from the target. Today, the number of governing units of the Vaccine Alliance has increased from 14 to 27, which is the mainstay of the development of China's vaccine industry. At this critical moment in the global fight against the epidemic, he suggests experts attending the meeting to actively offer suggestions and advices on how to achieve the ultimate goal of epidemic prevention and control, complete the task and mission of China's vaccine industry, and jointly fight the epidemic with global counterparts, produce vaccine as early as possible and as good as possible, guarantee supply and promote application and R&D, strengthen the development of China's vaccine industry and promote international cooperation against the epidemic.


Sun Yanrong, Deputy Director of the China National Center for Biotechnology Development of the Ministry of Science and Technology, said in her speech that science and technology are the most powerful weapon to overcome the COVID-19 epidemic. It can provide strong support to return life to normal. She talked about her feelings with several words featured by"100". First, in the past 100 years, China's vaccine products industry has gone through a 100-year development process. People have changed from passive immunization to active immunization, achieving a substantial increase in life expectancy. The second is 100 days. In the more than 100 days since the outbreak of the epidemic, more than a dozen scientific research teams in China have gone all out to develop vaccines day and night, not only fast but also good. It is precisely because of their efforts that we have made, five research and development teams' vaccines have entered the clinical trial stage today. Third are 100 people. In this scientific research, our country has laid out 5 vaccine research and development technical routes and 12 research and development teams. In addition, we still have 100 backbone personnel and 100 technicians working hard, which shows us the hope of getting out of the strait and overcoming the epidemic. Fourth are 100 projects. At present, more than 100 products are being developed around the world. We have seen the joint efforts of scientists around the world and the selfless dedication of entrepreneurs, contributing to the global war against epidemic. The fifth is score 100. I believe that the accumulation and precipitation of our vaccine industry over the past 100 years can really make new contributions to the development of safe and effective vaccines, prevent and control global epidemics, and protect of the life and health of all mankind.


In his speech, Director Wu Zhiyin of the Vaccine research and development committee for COVID-19 Prevention and Control and the Joint Prevention and Control Mechanism of the State Council pointed out that vaccines are the "ballast stones" for the global fight against the new crown epidemic. At present, important progress has been made in the research and development of the COVID-19 vaccine. He thanked all scientific research teams for their efforts in the research and development of the COVID-19 vaccine. However, vaccine research and development cannot be slackened at all. All scientific research teams should improve their strategic layout, focus on the future, work together, accelerate research and development, and strive for the early marketing of the COVID-19 vaccine.


Zhang Yuntao, vice president of China National Biotec Company Group, introduced the establishment of the vaccine alliance, its tasks and responsibilities, systematically introduced the research and development progress of the COVID-19 vaccine at home and abroad, and made a forecast and judgment on the future development of COVID-19 vaccine.


At the scene, Dr. Anita Zaidi, Director of the Vaccine Development Team of the Bill and Melinda Gates Foundation, Dr. David Kaslow, Vice President of Essential Drugs and Head of Vaccine Innovation and Accessibility Center of PATH, Dr. Philip Minor, former deputy director of the British National Institute for Biological Products Control (NIBSC), and Dr. Seth Berkley, president of the Global Alliance for Vaccines and Immunization (GAVI), also sent videos to the conference to affirm China's performance and contribution in the prevention and control of the epidemic.


Dr. Anita Zaidi, Director of Vaccine Development Department of Gates Foundation, said that he was glad to see China's great efforts and investment in the research and development of the COVID-19 vaccine. Chinese researchers have established various vaccine development pipelines, which reflects the firm commitment of China's public and private sectors to jointly cope with this huge global challenge. Dr. Anita Zaidi pointed out that the Gates Foundation will support Chinese partners in meeting the challenges of the pandemic and will jointly develop and deploy vaccines, drugs and diagnostic reagents to help the world.


David Kaslow, vice president of PATH, expressed great pleasure at the establishment of the China Vaccine Innovation Alliance and affirmed the progress of China's vaccine research and development and production capacity and its contribution to global health. He said that during his work with China's vaccine partners, PATH continues to see the great potential released by China's innovative forces. China has developed of more than 50 COVID-19 vaccines candidates, some of which are advanced at an unprecedented speed. It is hoped that Chinese vaccine companies will continue to make important contributions to the global supply of safe and effective vaccines.


Dr. Philip Minor, former deputy director of NIBSC, believes that China has strong scientific research capability and strong vaccine production capacity, and has developed a large number of vaccines suitable for special purposes in the country, such as hepatitis vaccine and EV71. These capabilities can be well applied to the development of COVID-19 vaccines.


Dr. Seth Berkley, President of GAVI, first expressed warm congratulations on China's success in containing the epidemic. He pointed out that the world is now facing the biggest public health crisis in 100 years, and the greatest hope to resolve this crisis is to develop vaccines. International cooperation will be the key to fighting the epidemic. The initiatives and innovations of the China Vaccine Alliance can make great contributions to global health and safety. GAVI looks forward to continuing to cooperate with Chinese manufacturers.


On behalf of China's Strategic Alliance for Technological Innovation in the Vaccine Industry, Zhang Yuntao read out a proposal to all colleagues in the vaccine industry. The proposal emphasizes that in the face of the complicated situation of the COVID-19 epidemic, vaccine enterprises should further play their role in fighting the epidemic, better fulfill their social responsibilities, jointly promote scientific and technological research on vaccines, ensure vaccine research and development, ensure the safety of vaccine application, and fully utilize the important role of vaccines in safeguarding public health and national security. To strengthen the construction of the whole vaccine industry chain, improve the overall level and ability of the vaccine industry to serve the society; We will promote international cooperation in vaccine research and development, join hands in the global fight against the epidemic, demonstrate the responsibility of major countries, jointly build a "human health community" with the people of the world, and join hands with other countries to deal with and defeat the global epidemic as soon as possible.


Academician Wang Junzhi of National Institution for Food and Drug Control and Chief Scientist of NIBSC Dr.Javier Martin made keynote speeches on research and development of the COVID-19 vaccine. After that, the participants discussed how to explore the full potential of the vaccine alliance. Finally, Yang Xiaoming summarized the discussion and said that in the future, he would further focus on the alliance's tasks and highlight the role of vaccines.


Attached is the governing unit of the Vaccine Alliance:

1, China National Biotec Company Group.

2, Advaccine ( Suzhou )Biotechnology Co 

3, Beijing Aimei Biological Vaccine Technology Group Co., Ltd.

4, Sinovac Biotech Co.,Ltd. 

5, Beijing Minhai Biotechnology Co., Ltd

6, Chongqing Zhifei Biological Products Co., Ltd

7, Fudan University

8, Guangxi Center for Disease Prevention and Control

9, He Nan Center for Disease Prevention and Control

10, Hualan Biological Engineering, Inc.

11, Jiang Su Center for Disease Prevention and Control

12, Institute of Bioengineering, Military Medical Research Institute

13, CanSino Biologics Inc.

14, Tsinghua University 15, Xiamen University 16, Stemirna Therapeutics Co., Ltd. 17, Sichuan University 18, Suzhou Abogen  Biotechnology Co., Ltd. 19, Walvax Biotechnology Co., Ltd.20, Changchun Bcht Biotechnology Co.21, Institute of Virus Disease Prevention and Control of China Center for Disease Control and Prevention 22,National Institute for Communicable Disease Control and Prevention Chinese Center for Disease Control and Prevention23,National Immunization Program Chinese Center for Disease Control and Prevention

24, Institut Pasteur of Shanghai Chinese Academy of Sciences

25, National Institutes for Food and Drug Control

26, Institute of Medical Biology Chinese Academy of Medical Sciences

27, Zhuhai Lifanda Biotechnology Co., Ltd. 


In order to accelerate vaccine research and development in China, promote the upgrading of key industrial technologies and the quality of vaccine products, strengthen the technological reserve of China's vaccine industry, improve the ability to deal with new and emergency epidemic outbreaks and abilities of disease prevention and control, and promote the healthy development of the vaccine industry, with the promotion and support of the Ministry of Science and Technology, China National Biotec Company Group, as the supporting unit of the alliance, led the establishment of a strategic alliance for Chinese vaccine industry technology innovation strategic alliance in 2013.